Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 pseudogene" is a genomic region that closely resembles the functional gene GALNT1, which encodes the enzyme **UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1** (commonly abbreviated as GalNAc-T1). However, this **pseudogene** does not encode a functional protein and is not an active participant in biological pathways, unlike the bona fide GALNT1 enzyme that catalyzes the initial step in mucin-type O-glycan biosynthesis[3][6]. As a pseudogene, it is not considered a therapeutic target, does not have known biological or disease roles, and does not interact with drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 pseudogene.